Individualized Dosing of Nifedipine For Tocolysis in Preterm Labor

Status Completed

Clinical Trial Summary

This study looks at the effects of a mother's genes and other characteristics (mother's age, baby's age, race, and other diseases) on the ability of nifedipine to end contractions and prevent an early delivery. This information will be used to decide what amount of nifedipine women need to best treat preterm contractions.

Clinical Trial Description

The purpose of this study is to identify the relationship between the amount of nifedipine in a woman's body and its effect on ending preterm (early) labor contractions and delaying delivery by at least 48 hours. The study will also look at the effects of genes (materials passed from parent to child that determine the make-up of the body) and other characteristics (for example mother's age, baby's age, race, and other diseases or drugs) on the ability of nifedipine to end the contractions. We will use this information to decide what amount of nifedipine women need to best treat preterm contractions. This study will also examine the effect of pregnancy on how fast nifedipine is removed from the woman's body.

This study will be conducted on two phases. The first will study women who are starting nifedipine for treatment of preterm labor. Nifedipine dose will be determined by the patient's physician. Blood samples will be obtained from the mother to determine the concentration of nifedipine and its metabolite, oxidized nifedipine, during one dosing interval. A blood sample will also be obtained for DNA isolation to examine variants in genes involved in the nifedipine pathway. We will also collect data on uterine contractions and blood pressure through clinical monitoring. After delivery, maternal and umbilical cord blood samples will be obtained, along with a piece of placenta. Women who take part in the first phase will be asked to return 6-10 weeks after delivery. At that time, she will take a single dose of 10 mg immediate release nifedipine by mouth and blood samples will be collected for up to 6 hours. Blood pressure will also be monitored prior to collection of each blood sample ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02090920
Study type	Observational
Source	Indiana University
Contact
Status	Completed
Phase
Start date	July 2011
Completion date	April 2019

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT06168149` - The Relationship of Fetal Lung Elastography Values With the Development of Respiratory Distress in Cases of Preterm Labor
Completed	`NCT02538718` - Efficacy and Safety of MgSO4 as Tocolytics Compared to Ritodrine in Preterm Labor	N/A
Not yet recruiting	`NCT05864066` - Cyclin-dependent Kinase Inhibitor 2A (Placental Senescence Marker) on Labor-related Signals
Terminated	`NCT03715530` - Use of Placental Alpha Microglobulin-1(PAMG-1) to Diagnose Premature Rupture of Membranes in Pregnant Women	N/A
Recruiting	`NCT03638037` - Correlation Between Maternal Vitamin D Level And Preterm Birth
Recruiting	`NCT03992534` - The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth	Phase 1
Completed	`NCT02536352` - Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being	Early Phase 1
Withdrawn	`NCT03122704` - Group B Streptococcus (GBS) Infection and in Preterm Labor Women Conceived Through IVF	N/A
Recruiting	`NCT01518816` - Role of Serum Total Antioxidant Level in Preterm Labor	N/A
Recruiting	`NCT04590677` - Prediction of the Onset of Term and Preterm Labour
Completed	`NCT03112018` - Strengthening Facility-based Intrapartum/Immediate Newborn Care to Reduce Mortality of Preterm Infants in Migori County, Kenya and Busoga Region, Uganda	N/A
Active, not recruiting	`NCT04301518` - Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs	N/A
Completed	`NCT03785795` - Multichannel EMG Diagnosing True Preterm Labor
Withdrawn	`NCT02351310` - Effectiveness of ACS in Extreme Preemies	Phase 3
Not yet recruiting	`NCT01985594` - Utrogestan Versus Nifedipine as Tocolysis for Preterm Labor: a Randomised Controlled Trial	Phase 2
Not yet recruiting	`NCT04532086` - Uterocervical Angle and Preterm Labour
Completed	`NCT04605172` - Lockdown Impact on Spontaneous Premature Birth in a Level III NICU
Recruiting	`NCT04417595` - Investigating N-3 Fatty Acids to Prevent Neonatal Tobacco-related outcomeS	Phase 2
Completed	`NCT03923023` - Impact of the PREEMI Package on Neonatal Mortality
Recruiting	`NCT06157203` - Labor Status Monitor for Diagnosing True vs False Labor in Preterm Patients

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.